BAGNEUX, France– Genomic Vision (the “Company” – FR0011799907 – GV) (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced that University of South Florida is implementing the full Molecular Combing workflow using FiberComb, FiberVision S and FiberStudio solutions.
Researchers at University of South Florida received National Institute for Health (NIH) funding to acquire Genomic Vision technology to implement the company’s replication combing assay workflows with an outlook to study more than 100 samples in the first year of the grant award using Molecular Combing.
Genomic Vision’s replication combing assay provides a clear read out of spatial and temporal characteristics of DNA replication that enables the characterization of universal and targeted genomic replication events providing researchers with critical DNA replication features such as initiation rate, replication fork velocity and replication fork progression.
In cancer studies, these features of DNA replication help in drug development because Molecular Combing allows a clear view of mechanistic understandings of genomic instabilities.
“Obtaining a better understanding of the mechanisms that maintain the stability of the human genome, including those that function at the interface between DNA replication, recombination and repair, is a very important part of our program with the NIH, especially as it relates to the Bloom syndrome DNA helicase and its interacting factors,” said Professor Kristina Schmidt, Professor of Cell & Molecular Biology at the University of South Florida. “Adding Molecular Combing to our laboratory expertise will help us expand our research on how DNA damage, unusual DNA structures, and changes in replisome composition affect DNA replication and give rise to genome instability and increased cancer risk”.
“Errors in DNA replication are the leading cause for mutagenesis and genome instability. Characterizing the mechanisms that control replication dynamics and fork stability in response to replication stress is the major focus of our NIH-aided program, and acquisition of this combing technology provides a whole new dimension to our research efforts” said Huzefa Dungrawala, Assistant Professor of Cell & Molecular Biology at the University of South Florida.
“The DNA replication analysis segment is a leading application for our Molecular Combing technology, enabling the research and biotechnology clients to obtain a clear read out of spatial and temporal characteristics of DNA replication.” said Dominique Remy-Renou, CEO of Genomic Vision. “We are thrilled to partner with University of South Florida to provide novel insights for structural variation and genomic rearrangement analysis in complex genetic disease research and drug development studies.”
